

Application No.
Reply to Office Action of

10/595,807 Amendment Dated
December 31, 2008

June 1, 2009

RECEIVED
CENTRAL FAX CENTER

JUN 01 2009

Remarks/Arguments:

Claims 1 to 13, 18-21, and 28 are pending in the instant application. Applicants have amended claims 1, 11, and 12. No new matter has been added by these amendments.

The Examiner has required restriction between two groups:

Group I: Claims 1-13, 18-21, and 28, drawn to compounds of Formula (I) where R⁶ and R⁷ are independent substituents (i.e. monocyclic pyrimidine compounds), corresponding process of preparation, method of use, and pharmaceutical composition; and

Group II: Claims 1-13, 18-21, and 28, drawn to compounds of Formula (I) where R⁶ and R⁷ together with the pyrimidine bond to which they are attached form a 5- or 6-membered ring (i.e. bicyclic pyrimidine compounds, e.g. quinazolines), corresponding process of preparation, method of use, and pharmaceutical composition.

Applicants hereby elect Group I, drawn to "compounds of Formula (I) where R⁶ and R⁷ are independent substituents (i.e. monocyclic pyrimidine compounds), corresponding process of preparation, method of use, and pharmaceutical composition."

Applicants have amended claims 1, 11, and 12 consistent with their election of Group I.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

A petition for a four-month extension of time is being filed herewith, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101256-1P US.

Application No.
Reply to Office Action of

10/595,807 Amendment Dated
December 31, 2008

June 1, 2009

Although Applicants believe no excess claim fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101256-1P US.

Respectfully submitted,



Name: John X Haberman
Dated: June 1, 2009
Reg. No.: 55,236
Phone No.: 781-839-4736
AstraZeneca Intellectual Property
AstraZeneca R&D Boston
35, Gatehouse Drive
Waltham, MA 02451